RT Journal Article
T1 Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study.
A1 Vincenzi, Bruno
A1 Napolitano, Andrea
A1 Fiocco, Marta
A1 Mir, Olivier
A1 Rutkowski, Piotr
A1 Jean-Yves, Blay
A1 Reichardt, Peter
A1 Joensuu, Heikki
A1 Fumagalli, Elena
A1 Gennatas, Spyridon
A1 Hindi, Nadia
A1 Nannini, Margherita
A1 Spalato-Ceruso, Mariella
A1 Italiano, Antoine
A1 Grignani, Giovanni
A1 Brunello, Antonella
A1 Gasperoni, Silvia
A1 De-Pas, Tommaso
A1 Badalamenti, Giuseppe
A1 Pantaleo, Maria A
A1 van-Houdt, Winan J
A1 IJzerman, Nikki S
A1 Steeghs, Neeltje
A1 Gelderblom, Hans
A1 Desar, Ingrid M E
A1 Falkenhorst, Johanna
A1 Silletta, Marianna
A1 Sbaraglia, Marta
A1 Tonini, Giuseppe
A1 Martin-Broto, Javier
A1 Hohenberger, Peter
A1 Le-Cesne, Axel
A1 Jones, Robin L
A1 Dei-Tos, Angelo P
A1 Gronchi, Alessandro
A1 Bauer, Sebastian
A1 Casali, Paolo G
K1 Adjuvants, Immunologic
K1 Chemotherapy, Adjuvant
K1 Gastrointestinal Stromal Tumors
K1 Imatinib Mesylate
K1 Neoplasm Recurrence, Local
K1 Retrospective Studies
AB The effect of high-dose imatinib (800 mg/day) on survival in the adjuvant treatment of patients with resected KIT exon 9-mutated gastrointestinal stromal tumors (GIST) is not established. Here, the association of dose and other clinicopathologic variables with survival was evaluated in a large multi-institutional European cohort. Data from 185 patients were retrospectively collected in 23 European GIST reference centers. Propensity score matching (PSM) and inverse-probability of treatment weighting (IPTW) were used to account for confounders. Univariate and multivariate unweighted and weighted Cox proportional hazard regression models were estimated for relapse-free survival (RFS), modified-RFS (mRFS) and imatinib failure-free survival (IFFS). Univariate Cox models were estimated for overall survival. Of the 185 patients, 131 (70.8%) received a starting dose of 400 mg/d and the remaining 54 (29.2%) a dose of 800 mg/d. Baseline characteristics were partially unbalanced, suggesting a potential selection bias. PSM and IPTW analyses showed no advantage of imatinib 800 mg/d. In the weighted multivariate Cox models, high-dose imatinib was not associated with the survival outcomes [RFS: hazard ratio (HR), 1.24; 95% confidence interval (CI), 0.79-1.94; mRFS: HR, 1.69; 95% CI, 0.92-3.10; IFFS: HR, 1.35; 95% CI, 0.79-2.28]. The variables consistently associated with worse survival outcomes were high mitotic index and nongastric tumor location. In this retrospective series of patients with KIT exon 9-mutated GIST treated with adjuvant imatinib, a daily dose of 800 mg versus 400 mg did not show better results in terms of survival outcomes. Prospective evaluation of the more appropriate adjuvant treatment in this setting is warranted.
PB American Association for Cancer Research
YR 2021
FD 2021-10-01
LK http://hdl.handle.net/10668/20185
UL http://hdl.handle.net/10668/20185
LA en
NO Vincenzi B, Napolitano A, Fiocco M, Mir O, Rutkowski P, Blay JY, et al. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clin Cancer Res. 2022 Apr 14;28(8):1672-1679.
DS RISalud
RD Apr 10, 2025